Skip to main content

Inhibikase Therapeutics, Inc 10-K for FY2022

Inhibikase Therapeutics, Inc. (IKT)

10-K 2023-03-31 For: 2022-12-31
View Original
Added on April 07, 2026

About this 10-K

Inhibikase Therapeutics, Inc filed this 10-K on March 31, 2023, covering the fiscal year ended December 31, 2022 (FY2022).

Headline figures

Fiscal year ended December 31, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$123.44K
down 96.0% from $3.1M a year earlier
Net loss
$18.05M
compared with a net loss of $14.79M a year earlier
Diluted EPS
-$0.72
compared with -$0.81 a year earlier